Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06349473 · ClinicalTrials.gov registry record · Phase 1
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
A Phase 1 study of Healthy Participants and Hemophilia A, sponsored by Equilibra Bioscience.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 10
- Study locations
NCT06349473 is a Phase 1 study of Healthy Participants and Hemophilia A that is actively recruiting participants, run by Equilibra Bioscience. The registered enrollment target is 31 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (52% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT06349473, a Phase 1 study of Healthy Participants and Hemophilia A, is actively recruiting participants, sponsored by Equilibra Bioscience.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SR604
Study Locations (10)
California
- California Clinical Trials Medical Group (CCTMG) - Glendale
- Children's Hospital Los Angeles - Los Angeles
Pennsylvania
- Penn State Milton S Hershey Medical Center Pediatrics - Hershey
- Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program - Philadelphia
Illinois
- Rush University Medical Center - Chicago
Louisiana
- LA Center for Bleeding and Clotting Disorders - Metairie - Metairie
Michigan
- University of Michigan Hospitals - Michigan Medicine - Ann Arbor
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- Brody School of Medicine at East Carolina University - Greenville
Ontario
- McMaster University Medical Centre, Hamilton Health Sciences - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2024-05-10 |
| Est. Completion | 2026-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06349473
The ClinicalTrials.gov registry entry for NCT06349473 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (52% lower). The listed sponsor is Equilibra Bioscience, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06349473 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Pennsylvania, Illinois.
Frequently Asked Questions
What is clinical trial NCT06349473 about?
NCT06349473 is a clinical study titled "A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII)...
What is the current status of trial NCT06349473?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2024-05-10. Estimated completion is 2026-09-28.
What conditions does trial NCT06349473 study?
This clinical trial studies the following conditions: Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency.
What interventions are being tested in trial NCT06349473?
The interventions under investigation include: Placebo (DRUG), SR604 (DRUG).
Who is sponsoring clinical trial NCT06349473?
This trial is sponsored by Equilibra Bioscience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06349473 being conducted?
This trial has 10 study locations across California, Illinois, Louisiana, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.